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Association of Epidermal Growth Factor Receptor
Activating Mutations with Low ERCC1 Gene Expression in
Non-small Cell Lung Cancer
David R. Gandara, MD,* Peter Grimminger, MD,† Philip C. Mack, PhD,* Primo N. Lara, Jr., MD,*
Tianhong Li, MD, PhD,* Peter V. Danenberg, PhD,‡ and Kathleen D. Danenberg, BSc§
Introduction: Patients with non-small cell lung cancer (NSCLC) with
cancers harboring activating mutations in the epidermal growth factor
receptor (EGFR) show improved efficacy from EGFR tyrosine kinase
inhibitors. Some clinical studies also suggest enhanced efficacy of
platinum-based chemotherapy in patients with EGFR-mutant can-
cers. We investigated the relationship of EGFR mutation status and
DNA repair capacity, as exemplified by excision repair cross-
complementing 1 (ERCC1) gene expression, as a potential explana-
tion for this observation.
Methods: Microdissected formalin-fixed paraffin-embedded tumors
from 1207 patients with NSCLC were analyzed by real-time poly-
merase chain reaction for mRNA expression levels of ERCC1 and
for EGFR mutation status by an allele-specific polymerase chain
reaction assay.
Results: NSCLC subtype was adenocarcinoma (AC) in 712 patients,
squamous in 175, and not otherwise specified or other in 320. EGFR
activating mutations were detected in 183/1207 patients (15.2%).
Median ERCC1 expression overall was 1.82 (range, 0.22–27.31)
and was histology related: AC, median  1.68 (0.22–11.33) and
squamous, median  2.42 (0.51–14.28) (p  0.001). Using a
previously defined reference level of 1.7, ERCC1 expression was
categorized as low in 556 of 1207 patients (46.1%). The presence of
EGFR mutations was highly associated with ERCC1 expression
(p  0.001). This association was retained when adjusting for AC
histologic subtype (p  0.001).
Conclusions: NSCLC specimens harboring EGFR activating muta-
tions are more likely to express low ERCC1 mRNA levels. Whether
these findings translate into enhanced clinical efficacy of EGFR-
mutant cancers to platinum-based chemotherapy remains to be
determined.
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(J Thorac Oncol. 2010;5: 1933–1938)
Platinum-based chemotherapy remains a standard of care foradvanced stage non-small cell lung cancer (NSCLC), result-
ing in improved survival, symptom control, and superior quality
of life compared with patients receiving best supportive care.1–3
Nevertheless, initial reports describing dramatic responses in
patients with chemotherapy-refractory NSCLC with cancers
harboring activating mutations in the epidermal growth factor
receptor (EGFR) to the EGFR tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib raised the question of whether chemother-
apy should remain the therapeutic standard in this biomarker-
defined subgroup.4–7
Subsequently, randomized clinical trials have been un-
dertaken to compare the efficacy of EGFR TKIs versus
platinum-based chemotherapy in the first-line therapy for
advanced NSCLC patient populations that are either EGFR
mutation positive or enriched for clinical-pathologic features
favoring EGFR mutation, such as East Asian ethnicity, fe-
male gender, and never-smoking status.8–10 Overall, these
trials support the conclusion that EGFR TKIs are superior to
initial chemotherapy in this biologically distinct NSCLC
subgroup, especially with respect to response rate and pro-
gression-free survival (PFS). In one such trial, Iressa Pan-
Asia Study (IPASS), in which gefitinib was compared with
carboplatin-paclitaxel chemotherapy in a clinically and
pathologically enriched NSCLC patient population, approxi-
mately 60% of patients with available tumor tissue (retro-
spectively tested) proved positive for EGFR activating mu-
tations.8 As anticipated, response rate and PFS in patients
with EGFR mutations were markedly increased compared
with chemotherapy. Nevertheless, efficacy in the chemother-
apy arm was also surprisingly good in the EGFR-mutant
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subgroup; the overall response rate to chemotherapy in pa-
tients with EGFR-mutant cancers was 47.3%, compared with
23.5% in patients with EGFR wild-type cancers. The clinical
implications of this finding have remained unclear. We hy-
pothesized an association between DNA repair capacity and
EGFR mutation status as a possible explanation. In this study,
we report analysis of a large tumor tissue database for the
purported predictive platinum biomarker excision repair
cross-complementing 1 (ERCC1), demonstrating that patients
with cancers harboring EGFR activating mutations are sig-
nificantly more likely to exhibit low gene expression levels of
ERCC1, a possible explanation for enhanced platinum-based
chemotherapy efficacy in this biologically distinct subgroup
of NSCLC.
METHODS
Patient Tumor Samples
Formalin-fixed paraffin-embedded tumor samples from
patients with NSCLC available from the Response Genetics,
Inc. (RGI) database were used for this analysis. In all cases,
central pathology review of submitted hematoxylin and eo-
sin-stained slides was conducted by a single pathologist to
estimate tumor load per sample and to verify NSCLC histo-
logic subtype as reported by the submitting institution. No
further testing was performed to distinguish cell type in cases
submitted as not otherwise specified (NOS).
Quantitative Real-Time Polymerase Chain
Reaction for ERCC1 mRNA Expression
RNA was isolated from microdissected tumor samples
following a proprietary procedure at RGI (Los Angeles, CA;
US patent No. 6248,535), a Good Laboratory Practices-
compliant and Clinical Laboratory Improvement Amend-
ments-certified commercial laboratory. Briefly, after exami-
nation of the hematoxylin and eosin-stained slides, 10-m
thick sections were stained with nuclear fast red to enable
visualization of histology for manual or laser capture micro-
dissection. Manual microdissection was performed by excis-
ing tumor cells from other tissue with a razor blade and a
dissecting microscope on tumor areas greater than 0.5 mm 
0.5 mm. Laser capture dissection was performed on smaller
areas as described previously and ensures that only tumor
cells were dissected (P.A.L.M. Microlaser Technologies AG,
Munich, Germany).11 RGI has validated that manual tech-
niques are equivalent to laser technology when tumor areas
are greater than 0.5 mm  0.5 mm.
The resulting tumor RNA was reverse transcribed into
cDNA. Expression of ERCC1 and ACTB (Beta-actin, endog-
enous reference) was quantified by real-time fluorescence
detection of amplified cDNA (ABI PRISM 7900 Sequence
Detection System [TaqMan], Perkin-Elmer Applied Biosys-
tems, Foster City, CA). The real-time polymerase chain
reaction assay was conducted as described previously.11,12 All
primers were selected using Gene Express software (Applied
Biosystems, Foster City, CA) but were adapted to the require-
ments of cDNA generated from RNA. Previously published
sequences of ERCC1 and ACTB were used, and all primers
were validated following a previously described protocol.11,12
All analyses were conducted on all samples in triplicate. The
detection of amplified cDNA results in a cycle threshold (Ct)
value, which is reciprocal to the amount of cDNA contained
in the sample. Normal colon, liver, and St. Universal Mix
RNA (Stratagene, La Jolla, CA) were used as control cali-
brators on each assay plate. Gene expression levels were
described as the ratio between two absolute measurements
(gene of interest/endogenous reference gene) to control for
intersample variation. Before statistical analysis, all ratios
were logarithmically transformed including a multiplier,
which counted the average cycle threshold values obtained
for each gene during the validation process. This procedure
facilitated the comparison of samples, which were run on
different assay plates.
Scorpion-ARMS for EGFR Mutation Analysis
RGI generated and validated a laboratory developed
test using reagents from Qiagen’s EGFR29 Mutation test kit,
according to manufacturer’s instructions. Real-time polymer-
ase chain reaction assays were performed using DNA ex-
tracted from formalin-fixed paraffin-embedded samples to
detect wild-type or mutant EGFR molecules. By comparing
control and mutant sample reactions within our validated
range, we were able to detect low levels of mutation of EGFR
(1% mutant in a background of wild-type genomic DNA).13,14
The reagents enabled the detection of the following muta-
tions: 19del, L858R, L861Q, G719X, S768I, and three inser-
tions in exon 20.
Statistical Analyses
The Mann-Whitney U test was used to determine sig-
nificant associations between continuous variables (i.e., gene
expression) and dichotomous variables (i.e., mutation status).
Fisher’s exact test was used to calculate the significance of
associations between two dichotomous variables.
An ERCC1 cut-point value optimized for segregating
patient responsiveness to platinum-based therapy in NSCLC
was used, as previously described using the maximal 2
method.11 The level of significance was set to p  0.05. All
p values reported were based on two-sided tests. All statisti-
cal analyses were performed using the Software Packages
SPSS for Windows (Version 17.0, Chicago, IL) and JMP 7.0
Software (SAS, Cary, NC).
RESULTS
Patient Characteristics
Specimens from 1207 patients with NSCLC for whom
both ERCC1 gene expression levels and EGFR mutation
status were available form the data set for this analysis. By
histologic subtype, 712 were adenocarcinomas (ACs), 175
were squamous cell carcinomas, and 320 were NOS or other.
Table 1 presents patient characteristics available within the
RGI database. Treatment regimens used and therapy-related
outcomes were not available for this data set.
Association of EGFR Mutation Status with
ERCC1 Gene Expression
Median ERCC1 mRNA expression was 1.82, with a
large intrapatient variability (range, 0.22–27.31) (Table 2).
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ERCC1 expression levels were associated with NSCLC his-
tologic subtype.15,18 For ACs, the median expression level
was 1.68 (0.22–11.33), whereas for squamous cancers, the
median was 2.42 (0.51–14.28), p  0.001. In the NOS/other
category, the median ERCC1 level was intermediate: 1.85
(0.45–27.31). ERCC1 levels were categorized as low (below
the reference level of 1.7) in 556 of 1207 patients (46.1%),
using a previously described cut point.15,16 Significantly more
ACs were below 1.7 compared with squamous cell cancers
(p  0.001) (Figure 1).
Results of EGFR mutation testing showed that 1024 of
1207 specimens were wild type, and 183 were positive for
activating mutations (15.2%). Most common were exon 19
deletions (E19del) and L858R missense mutations at 106 of
183 (58%) and 56 of 183 (31%) patients, respectively. Other
less common EGFR mutations identified were G719X (pres-
ence of G719S, G719A, or G719C), exon 20 insertions (not
distinguished), and L861Q. The great majority of EGFR muta-
tions were observed in ACs (144/183, 79%). Within the overall
AC population, EGFR-mutant tumors comprised 144 of 712
(20.2%). Only four EGFR activating mutations were found in
the 175 patients with squamous cell cancers, 2.3% (three with
E19del and one with L858R). In the NOS/other category, EGFR
mutations were detected in 35 of 320 (10.9%).
As presented in Table 3, EGFR mutation status was
significantly associated with ERCC1 gene expression levels
(p  0.001 by Mann-Whitney U test). In EGFR-mutant
versus wild-type cancers, median ERCC1 expression levels
were 1.47 (range, 0.32–8.24) and 1.88 (range, 0.22–27.31)
respectively. Although ERCC1 expression levels were gen-
erally lower in ACs overall, the association of EGFR muta-
tion status and ERCC1 expression was preserved when the AC
subset was analyzed separately (p  0.001 in ACs). EGFR-
mutant cancers were also more likely to be categorized as
ERCC1 low (1.7) and, therefore, platinum sensitive, p 
0.002 by two-sided Fisher’s exact test. In the cohort of patients
TABLE 1. Patient Characteristics
Histology
Adenocarcinoma (AC) 712 (59%)
Squamous cell carcinoma (SCCA) 175 (14.5%)
NOS/other 320 (26.5%)
Age, yr
Median 67
Range 18–96
Gender
Male/female 541 (44.8%)/666 (55.2%)
Stage
Early/late 2 (1%)/1205 (99%)
NOS, not otherwise specified.
TABLE 2. ERCC1 Gene Expression Levels by Histology
ERCC1 mRNA
Expression
Histology
NSCLC (All)
(N  1207)
AC
(N  712)
SCCA
(N  175)
NOS/Other
(N  320)
Median 1.82 1.68a 2.42 1.85
Range 0.22–27.31 0.22–11.33 0.51–14.28 0.45–27.31
a AC vs. SCCA: p  0.001.
NSCLC, non-small cell lung cancer; AC, adenocarcinoma; SCCA, squamous cell
carcinoma; NOS, not otherwise specified; ERCC 1, excision repair cross-complementing 1.
FIGURE 1. Distribution of excision repair cross-comple-
menting 1 (ERCC1) mRNA expression levels by histology
and epidermal growth factor receptor (EGFR) mutation sta-
tus. ERCC1 mRNA expression levels, normalized to the en-
dogenous standard ACTB, were plotted on the y axis in log
2. Patients were subdivided into four categories based on
EGFR mutation status (wild-type [WT] versus mutant [MT])
and histology: adenocarcinoma (AC) versus squamous cell
carcinoma (SCCA). In EGFR-WT tumors, ERCC1 levels were
significantly higher in SCCA compared with AC (p  0.001).
Significant differences were also observed between AC with
WT EGFR versus AC with mutant EGFR (p  0.001), with
ERCC1 levels lower in the EGFR-MT subpopulation. The
small number of SCCA harboring EGFR mutations precluded
statistical analysis.
TABLE 3. Comparison of ERCC1 Gene Expression with
EGFR Mutation Status
ERCC1 EGFR MT EGFR WT p
All NSCLC N  183 N  1024
Median 1.47 1.88 0.001
Range 0.32–8.24 0.22–27.31
AC N  144 N  568
Median 1.42 1.71 0.001
Range 0.32–5.1 0.22–11.33
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; AC,
adenocarcinoma; ERCC 1, excision repair cross-complementing 1.
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with wild-type EGFR, ERCC1 was significantly lower in AC
compared with squamous cell carcinoma (p  0.001).
ERCC1 expression was lower in cancers containing
E19del (n  106): median 1.35 (0.32–4.43) versus all other
EGFR activating mutations (n  77): ERCC1 median  1.69,
but this difference does not reach statistical significance (0.36–
8.24), p  0.124 (Mann-Whitney U test). Similarly, of the two
main types of EGFR mutations identified, ERCC1 expression
trended toward lower in E19del versus L858R: median  1.56
(0.36–8.24) (p  0.124, Mann-Whitney U test).
DISCUSSION
Alterations in DNA repair capacity, most commonly
related to ERCC1 mRNA or protein expression levels, have
been reported to have both prognostic significance and pre-
dictive value for platinum-based chemotherapy in patients
with NSCLC.16–21 Although low levels of ERCC1 expression
translate into an unfavorable prognosis, conversely, low
ERCC1 levels are associated with improved efficacy of plat-
inum-based chemotherapy.16,19,21 In this study, we report for
the first time an association of EGFR mutation status and
ERCC1 mRNA expression levels. The great majority of
EGFR mutations consist of either in-frame deletions in exon
19 (E19del) or point mutations with substitution of arginine
for leucine at amino acid 858 (L858R).4–6,22 Activating
EGFR mutations confer responsiveness to EGFR TKIs
through enhanced drug interaction with the adenosine
triphosphate-binding site of the tyrosine kinase domain.4–6
The question of whether patients with NSCLC harboring such
tumor mutations are also more responsive to chemotherapy
has been raised by the results of the recent IPASS trial and
other studies. An association between EGFR activating mu-
tations and ERCC1 expression levels would provide a partial
explanation and a mechanism-based rationale for such obser-
vations. Nevertheless, a more basic explanation for this as-
sociation remains unclear.
It has been postulated that impaired nuclear excision
repair may be associated with increased genomic instability
and increased tumor mutation rates.19 Nevertheless, EGFR-
mutant cancers are generally devoid of the complex genetic
abnormalities, which relate to tobacco carcinogenesis.23 Nev-
ertheless, EGFR and DNA repair pathways have been linked
in preclinical studies, possibly through BRCA1, with impli-
cations for platinum-based therapy.24–26 Along this line, cis-
platin-induced cytotoxicity has been shown to be dependent
on EGFR-directed signaling, resulting in increased platinum-
DNA adducts in high EGFR-expressing cell lines.27 Rela-
tively few data exist on whether EGFR-mutant NSCLC cell
lines are more sensitive to DNA-damaging chemotherapy or
ionizing radiation in preclinical models.28–30 Sordella et al.28
reported that EGFR mutations were associated with activa-
tion of antiapoptotic pathways, resulting in decreased sensi-
tivity to a variety of chemotherapeutic agents in vitro,
whether DNA damaging or other. On the other hand, Das et
al.29 indicate that EGFR mutation enhances sensitivity to
radiation by a multifaceted process, including delayed DNA
repair kinetics, suggesting that other components of the DNA
repair mechanism may be involved in this association. In
accordance with this view, among patients with locally ad-
vanced NSCLC treated with radiation and platinum-based
chemotherapy, those with EGFR-mutant cancers have re-
cently been reported to have reduced local-regional tumor
failure compared with EGFR wild-type cancers (19% versus
46%) and trends toward improved survival: median 62.8
months versus 37.7 months (p  0.12).31
The overall incidence of EGFR activating mutations
within our data set, 15% (183 of 1207), may seem somewhat
high, when compared with that expected within the general
U.S. populations of patients with NSCLC. If so, a likely
explanation is that the series reported here is partially derived
from the RGI testing center and may reflect a patient sub-
group more likely to harbor EGFR mutations. As expected,
the two most common EGFR mutations identified in this
series are E19del and L858R mutations. One intriguing find-
ing is that cancers with E19del tended to have even lower
expression levels of ERCC1, when compared with all others
or to L858R mutant cancers, although the differences do not
reach statistical significance. Patients with cancers harboring
E19dels seem to be the most responsive to EGFR TKIs.32,33
In view of our findings, it is possible that a favorable response
profile for E19del cancers extends to platinum-based chemo-
therapy as well.
In addition to IPASS, some other reports directed
toward NSCLC in patients with EGFR mutations also suggest
that platinum-based chemotherapy may be advanta-
geous.34–37 For example, in a report by Hotta et al.34 in
patients with advanced NSCLC receiving first-line chemo-
therapy, PFS was improved in those with activating EGFR
mutations compared with those with wild-type cancers:
6-month PFS of 45.8% versus 21.9% (p  0.0422 in multi-
variate analysis). Response rate also tended to be higher, 21%
versus 15%, although this difference was not significantly
different. Further support is provided by a report in Taiwan-
ese patients with EGFR activating mutations receiving first-
line chemotherapy, which showed higher response rates with
platinum-based therapy versus nonplatinum therapy, 30%
versus 9.4%, p  0.023.36
Of interest, in a series of surgically resected patients
with NSCLC from Korea, Lee et al. have reported that EGFR
mutations were more frequent in cancers graded as ERCC1
negative for protein expression by immunohistochemistry. In
this series, EGFR mutations were present in 30% of ERCC1-
negative cancers versus 12.5% of ERCC1-positive tumors
(p  0.014).38 This report differs from our own in several
aspects. First, it assessed ERCC1 by immunohistochemistry-
based protein expression rather than mRNA expression lev-
els. Second, the relatively small patient population of 25
patients described in this report consists of early-stage can-
cers, whereas our population is made up almost entirely of
advanced stage patients. Nevertheless, the conclusion that
ERCC1 expression is linked to EGFR mutation status is
common to both reports.
Several potential alternative explanations exist to ex-
plain good patient outcome in patients with NSCLC with
EGFR activating mutations, unrelated to our findings. First,
not all clinical trials applicable to this question have sug-
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gested better than expected chemotherapy efficacy in patients
with EGFR-mutant NSCLC. For example, in the First-line
Single-agent Iressa vs Gemcitabine and cisplatin trial in
Never-smoklers with Adenocarcinoma of the Lung (First-
SIGNAL), a Korean trial comparing gefitinib to gemcitabine-
cisplatin chemotherapy in a clinical-pathologic selected pop-
ulation similar to IPASS, those patients with EGFR mutations
randomized to chemotherapy had a response rate of 37.5%,
when compared with 51.9% in EGFR mutation-negative
patients.39 Other studies reporting favorable PFS or overall
survival in patients with EGFR-mutated cancers receiving
platinum-based chemotherapy may be confounded by the
good prognosis portended by EGFR mutation positive status.
In the WJTOG3405 study, for example, consisting entirely of
EGFR-mutant-positive NSCLC, patients were randomized to
gefitinib or docetaxel-cisplatin as first-line therapy. In the
chemotherapy arm, the response rate was 32.2% not too
dissimilar from that of first-line platinum-based chemother-
apy in a general population of advanced stage NSCLC.
Nevertheless, disease control rate was favorable at 78%, with
a median PFS of 6.3 months and overall survival not yet
reached at 15 months.9
As noted earlier, EGFR mutation positivity portends a
good prognosis independent of therapeutic intervention, and
EGFR mutation-positive cancers are more commonly found
in younger patients and females who are never smokers, a
group having fewer comorbidities. Finally, EGFR mutations
are largely mutually exclusive of KRAS mutations, an addi-
tional molecular abnormality portending a poor prognosis.23
In summary, we report a significant association be-
tween EGFR mutation status and low ERCC1 gene expres-
sion levels in this retrospective analysis of a large tumor
tissue database. Therapeutic implications of this association
largely remain to be determined, as patient outcomes were
not available within our database. An already-initiated mo-
lecular profiling trial with a highly annotated patient database
regarding therapeutic outcomes, Collaborative Advanced
Stage Tissue Lung Cancer (sponsored by the Bonnie J.
Addario Lung Cancer Foundation [BJALCF] and it’s re-
search arm ALCMI [Addario Lung Cancer Medical Insti-
tute]), is equipped to address this association in a prospective
manner.
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